Bioengineered exosome-mRNA hybrids: a breakthrough in targeted miRNA delivery for diabetic kidney fibrosis therapy
These findings identify PARP1 as a key regulator of podocyte injury in DN via the TGFβ/Smads pathway and support the biomimetic receptor-relevant siRNA platform as a promising targeted therapeutic strategy for diabetic nephropathy.
Authors
- Jing Ke (ORCID: https://orcid.org/0000-0003-4188-7122)
- Jili Xing
- Shaochun Zhang
- Lei Cao
Institutions
- Ezhou Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Bioengineering and Biotechnology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3389/fbioe.2026.1709588
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Hubei Province